Premature ejaculation pill sold out in Singapore within first month

SINGAPORE - Within its first month of release, the premature ejaculation (PE) pill, Priligy, has sold out in Singapore.

Premature ejaculation (PE) is believed to be one of the most common male sexual health problems globally.

About one in three men in Singapore suffer from PE, according to a study on Premature Ejaculation Prevalence and Attitudes (PEPA) of Singapore men.

Priligy, to be taken orally, boasts the ability to treat one of the most common male sexual health problem.

The survey conducted prior to the launch of Priligy also found that 77 percent with PE never discussed their sexual health with a medical practitioner.

Its strong sales indicate that a growing number of local men are willing to discuss treatment options with doctors, says manufacturer, Janssen, a subsidiary of pharmaceutical giant Johnson & Johnson.

There could also be growing recognition that PE is a medical problem.

"PE is a recognized medical condition and treatments exist to help PE sufferers," said Dr Lim Kok Bin, Specialist in Urology at the Raffles Hospital UroRenal Centre.

He added that PE is not caused by inexperience or lack of willpower.

Moreover, local men may be more willing to deal with the general embarrassment they might feel if they seek medical help.

"Men tend to avoid talking about sexual matters with their physicians because of the stigma associated with the condition, and women seem reluctant to raise the issue with their men," Dr. Lim explained.

"If a couple believe PE is an issue that is causing distress to one or both partners, they should talk to each other and discuss it with their healthcare professional," noted Dr. Lim.

About Priligy

Priligy is an oral tablet tablet that can be taken 1 to 3 hours prior to engaging in sexual activity, once a day.

Patients should use Priligy only on the recommendation of their healthcare professional, and should only purchase Priligy from medical practitioners such as GPs and specialists.

This form of treatment is available to men aged between 18 to 64.